These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 698929)

  • 61. Evaluation of cellular immunologic responsiveness in the clinical management of patients with prostatic cancer. II. Effect of oestrogen, cryosurgery and transurethral resection on thymic-dependent lymphocytic blastogenesis.
    Ablin RJ; Guinan PD; Bruns GR; Sheik HI; Sadoughi N; Bush IM
    Urol Int; 1976; 31(5):383-400. PubMed ID: 1087494
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Male breast carcinoma following estrogen therapy: report of a case.
    Srinivasan G; Srinivasan U; Greiver P
    J Ky Med Assoc; 1979 Jan; 77(1):9-10, 48. PubMed ID: 215683
    [No Abstract]   [Full Text] [Related]  

  • 63. The immune response to prostate cancer: an evaluation and a review.
    Guinan P; Bhatti R; Sharifi R; Sundar B; Nagubadi S; Baumgartner G
    J Surg Oncol; 1980; 15(4):309-18. PubMed ID: 7005544
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Cryo-immunological response in prostatic cancer].
    Martínez-Piñeiro JA; Ruíz F; Hidalgo L; Muntañola P
    Actas Urol Esp; 1978; 2(1):23-32. PubMed ID: 665346
    [No Abstract]   [Full Text] [Related]  

  • 65. Hormonal epidemiology of prostatic cancer.
    Ablin RJ
    Med J Aust; 1977 Mar; 1(13):462-4. PubMed ID: 865362
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Evaluation of cellular immunologic responsiveness in the clinical management of patients with prostatic cancer. I. Thymic-dependent lymphocytic blastogenesis.
    Ablin RJ; Bruns GR; Guinan PD; Bush IM
    Urol Int; 1976; 31(5):374-82. PubMed ID: 64009
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Serum proteins in prostatic cancer. II. Effect on in vitro cell-mediated immunologic responsiveness.
    Ablin RJ; Guinan PD; Bruns GR; Sadoughi N; Bush IM
    Urology; 1975 Jul; 6(1):22-9. PubMed ID: 1145920
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Serum proteins in prostatic cancer VI. Reduction of the suppressive ("blocking"?) properties of serum on in vitro parameters of cell-mediated immunologic responsiveness following cryosurgery.
    Ablin RJ
    Urol Int; 1977; 32(1):65-73. PubMed ID: 70099
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Leukocyte adherence inhibition and immunoreactivity in prostatic cancer. I. Identification of anti-tumour cell-mediated immunity and "blocking" factor.
    Ablin RJ; Bhatti RA; Bruns GR; Guinan PD
    Eur J Cancer (1965); 1977 Jul; 13(7):699-703. PubMed ID: 598395
    [No Abstract]   [Full Text] [Related]  

  • 70. Immunomodulatory effect of cyclophosphamide on host humoral immunity in Dunning's R-3327 adenocarcinoma of the prostate.
    Bhatti R; Ray P; Bell N
    Urol Res; 1991; 19(1):15-8. PubMed ID: 2028560
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Effect of hormone therapy on immune response in patients with prostatic cancer.
    Guinan PD; Ablin RJ; Nourkayhan S; Bruns GR; Bush IM
    Urology; 1975 Dec; 6(6):693-6. PubMed ID: 1202718
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Estrogen-induced hypernephroma.
    Bellet RE; Squitieri AP
    J Urol; 1974 Aug; 112(2):160-1. PubMed ID: 4843321
    [No Abstract]   [Full Text] [Related]  

  • 73. Immunosuppression of cell- and serum-medicated tumour-associated immunity in prostatic cancer by human seminal plasma.
    Ablin RJ; Bhatti RA; Bush IM; Guinan PD
    Eur J Cancer (1965); 1980 Jun; 16(6):775-80. PubMed ID: 7408927
    [No Abstract]   [Full Text] [Related]  

  • 74. Delayed cutaneous hypersensitivity in patients with prostatic adenocarcinoma.
    Huus JC; Kursh ED; Poor P; Persky L
    J Urol; 1975 Jul; 114(1):86-7. PubMed ID: 1142506
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Leydig cell tumor in patient on estrogen therapy.
    Deshmukh AS; Hartung WH
    Urology; 1983 May; 21(5):538-9. PubMed ID: 6857903
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Migration-inhibitory effect of serum from patients with prostatic cancer.
    Ablin RJ; Bruns GR; Guinan PD; Bush IM
    Oncology; 1974; 30(5):423-8. PubMed ID: 4142651
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Inhibition of leukocyte migration by serum from patients with prostatic cancer.
    Ablin RJ; Guinan PD; Bush IM; Bruns GR
    Allergol Immunopathol (Madr); 1975; 3(6):379-84. PubMed ID: 56882
    [No Abstract]   [Full Text] [Related]  

  • 78. Liver damage and estrogen therapy of prostatic cancer. Case report.
    Kontturi M; Sotaniemi E; Ahlqvist J
    Scand J Urol Nephrol; 1972; 6(3):289-94. PubMed ID: 4629449
    [No Abstract]   [Full Text] [Related]  

  • 79. Effect of estrogen on the mixed lymphocyte reaction in normal individuals and prostatic cancer patients.
    Herr HW
    Prostate; 1982; 3(1):17-21. PubMed ID: 6210901
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Liver disorder owing to estrogen therapy in prostatic cancer, examined histopathologically in six autopsy cases].
    Yamauchi T; Kokuho M; Yoshino S; Tachibana Y; Kawai T; Kitagawa T
    Nihon Hinyokika Gakkai Zasshi; 1989 Dec; 80(12):1706-12. PubMed ID: 2625817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.